Question special
Lead Moderator

Thank you for joining our @NEJM discussion on the recently published study entitled, “Adnexanet alfa for the reversal of factor Xa inhibitor activity.” I would like to thank Dr. Crowther for joining us to discuss this article, as well as all of our expert panelists.

I would like to begin our discussion by asking Dr. Crowther, and our expert panel, a general question: Why is it important to have an antidote for the direct, oral anticoagulants? More specifically, why is this preferable to a factor replacement approach (PCC, etc)?

Perhaps you could also comment on the bleeding risk of the direct, oral anticoagulants relative to warfarin, as well as the importance of the relatively short half-life of these agents.